Skip to main content
$4.00 $0.03 (0.8%)

04:00 PM EDT on 10/22/21

PhaseBio Pharmaceuticals (NASDAQ:PHAS)

CAPS Rating: No stars

Current Price $4.00 Mkt Cap $190.7M
Open $3.97 P/E Ratio 0.00
Prev. Close $4.00 Div. (Yield) $0.00 (0.0%)
Daily Range $3.90 - $4.03 Volume 427,389
52-Wk Range $2.60 - $5.83 Avg. Daily Vol. 406,749

Caps

How do you think NASDAQ:PHAS will perform against the market?

Add Stock to CAPS Watchlist

All Players

4 Outperform
1 Underperform
 

All-Star Players

0 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:PHAS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

SmartAce (98.60)
Submitted April 10, 2019

I hate when I ask an assassin to kill my oldest and most powerful enemy and he begins stabbing me, revealing a painful truth.

NASDAQ:PHAS VS S&P 500 (SPY)

NASDAQ:PHAS Summary

Recent Community Commentary

Read the most recent pitches from players about PHAS.

No one has written a Pitch for PHAS stock yet. Tell us why you think PHAS will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in PHAS.

Score Leader

HDTVBG

HDTVBG (68.52) Score: +141.70

The Score Leader is the player with the highest score across all their picks in PHAS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
zzlangerhans 99.01 4/9/2019 Underperform 1Y $15.76 -74.65% +57.50% +132.15 0 Comment
naughtyguy 30.59 7/15/2021 Outperform 5Y $3.54 +12.85% +4.23% +8.62 0 Comment
stainsolution 55.76 11/29/2019 Outperform 5Y $3.19 +25.24% +43.92% -18.69 0 Comment
TMFGBudwell 64.95 4/25/2019 Outperform 5Y $12.82 -68.84% +55.13% -123.96 0 Comment
JCBC8385 40.59 4/25/2019 Outperform 5Y $13.31 -69.98% +54.97% -124.95 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PHAS.